NEOVACS Euronext Paris

Equities

ALNEV

FR001400HDX0

Biotechnology & Medical Research

End-of-day quote Euronext Paris Other stock markets 06:00:00 2024-02-04 pm EST			5-day change	1st Jan Change
1.98 ^EUR	-1.00%		-1.00%	-1.00%

Apr. 30

Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2023

Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2021

May 02, 2022 at 04:20 pm EDT

Neovacs S.A. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was EUR 0.034275 million compared to EUR 0.031309 million a year ago. Net loss was EUR 11.84 million compared to EUR 6.14 million a year ago.

Latest news about NEOVACS

Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2023

Apr. 29

Chart NEOVACS

Duration

Period

More charts

Company Profile

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.56%	46.71B
IQVIA HOLDINGS INC.	-1.51%	41.52B
LONZA GROUP AG	+48.83%	41.8B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B
MEDPACE HOLDINGS, INC.	+26.45%	11.98B
BIO-TECHNE CORPORATION	-0.14%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B

Other Biotechnology & Medical Research